RegulatoryRegulatoryPHN-03142026-09-28 16:43 CT
FDA Approves First Treatment for MCT8 Deficiency
Source · FDA press releases
TLDR
The FDA announced approval of Emcitate (tiratricol) for peripheral thyrotoxicosis, identifying it in the headline as the first treatment for MCT8 deficiency. The excerpt is truncated and provides too little detail to summarize the eligible population or supporting evidence.
01—Key points
- 01The approved product is Emcitate (tiratricol) tablets for oral suspension.
- 02The FDA describes peripheral thyrotoxicosis as excess thyroid hormone levels in the blood.
Why it matters Editorial
The announcement identifies a first treatment for MCT8 deficiency, but the provided text does not establish relevance to any listed peptide.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
No related news yet.